Beste apotheek van Nederland

Study/patient Characteristics
Cavallini 2004
Men >60 with
symptoms of
androgen
decline
Number of
patients with
full erections
and
satisfactory
intercourse at
1 month
Treatment
type
Number of
patients at
baseline
Intervention
Group 1
66.7%
(28/42)
All patients
84.2%
(16/19)
Psychogenic
55.6%
(10/18)
Vascular
40% (2/5)
Neurogenic
T (oral) 160
mg/d
Intervention
Group 2
31% (13/42)
All patients
57.9%
(11/19)
Psychogenic
11.1% (2/18)
Vascular
0% (0/5)
Neurogenic
Propionyl-L
Carnitine +
Acetyl-L
Carnitine 2
g/d
40 45
Intervention Intervention
Group 3 Group 4
-
-
NA
NA
- -
IIEF 4 (3–6) 4 (3–7)
Intercourse
satisfaction): - -
Median score
at baseline
IIEF 5 (3–10) 6 (3–10)
Intercourse
satisfaction: p <0.01 vs. p <0.01 vs.
Median score baseline baseline - -
at end of
therapy (6
months)
Table 24: Testosterone (T) Combined with PDE–5 inhibitors: Improvement in
Sexual Intercourse Outcomes
Study/patient Characteristics
Shabsigh 2004
Hypogonadal
men, nonresponders
to
sildenafil
therapy
Testosterone
Group
Treatment type T 1% gel +
Sildenafil
100mg
Control
Group
Placebo gel +
Sildenafil
100mg
Number of patients
at baseline 39 36
Mean number of
successful sexual
attempts per week
Relative risk (RR)
or weighted
mean difference
(WMD) [95% CI]
1.7–2.1 1.5–2.4 –
164